Research Options:
Week of Expected Pricing Pending
Company Name BELLUS Health Inc
Proposed Ticker BLU
CUSIP 07987C204
Business Description A clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
Lead Underwriter N/A
Co-Managers N/A
Initial Shares 6,00,00,000
Revised Initial Shares N/A
Initial Price $0.95-$0.95
Revised Price N/A
Final Price N/A
Final Ticker N/A

 

 
   
  © 2024 ICE Data Services. All rights reserved.